Paclitaxel is known to be active as a single and combination agent in esophageal cancer, and
has also been demonstrated to have anti-angiogenic properties in weekly dosing regimens.
Sunitinib malate is an anti-angiogenic drug with the potential to improve responses when
combined with chemotherapy, as demonstrated with other regimens in similar settings. We
believe that the combination of paclitaxel and sunitinib malate offer great promise in the
treatment of advanced esophageal cancer.